WUXI BIO (02269): Miao Jingwen appointed as non-executive director.
Wu Yibing, Ph.D., has resigned as of November 20, 2024, in an announcement from WuXi Biologics (02269).
WUXI BIO (02269) announces that, effective from November 20, 2024, Dr. Wu Yibing has resigned as a non-executive director and member of the Board's decision-making committee to dedicate more time to other personal matters. Ms. Miao Jingwen has been appointed as a non-executive director and member of the decision-making committee.
Related Articles
SSY GROUP (02005) obtained the drug production registration approval from the National Medical Products Administration for the fat-soluble vitamin injection () (10ml).
R&F Properties (02777) total sales revenue for February was approximately 750 million yuan, a decrease of 5.66% year-on-year.
At the end of February, the net asset value per share of comprehensive assets of C FIN INT INV (00721) was approximately 0.02 Hong Kong dollars.
SSY GROUP (02005) obtained the drug production registration approval from the National Medical Products Administration for the fat-soluble vitamin injection () (10ml).
R&F Properties (02777) total sales revenue for February was approximately 750 million yuan, a decrease of 5.66% year-on-year.
At the end of February, the net asset value per share of comprehensive assets of C FIN INT INV (00721) was approximately 0.02 Hong Kong dollars.
RECOMMEND
“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026
Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026
U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026
